Cleo Diagnostics (ASX:COV) has entered the analytical validation phase for its ovarian cancer test, progressing toward an FDA 510(k) submission expected in early 2027.
- Analytical validation phase commenced following assay development
- Three-batch validation to demonstrate assay reproducibility
- Clinical validation preparations underway for FDA submission
- FDA submission targeted for first half of 2027
- Manufacturing partnership with Bio-Techne supports test kit production
Analytical Validation Marks Regulatory Milestone
Cleo Diagnostics Limited (ASX:COV) has officially moved into the analytical validation (AV) phase for its ovarian cancer diagnostic test, a critical step on the path to FDA clearance. This transition follows the completion of commercial assay development and preparatory activities, setting the stage for formal data collection under FDA-mandated validation protocols. The company expects this phase to begin next month with the arrival of the first batch of test kits manufactured by Bio-Techne.
Three-Batch Validation to Prove Consistency
The AV study will assess three independently manufactured production batches to demonstrate assay reproducibility, manufacturing consistency, and overall analytical robustness. This rigorous approach aligns with FDA requirements and represents a shift from earlier research and development work to formal regulatory validation. Cleo has also expanded its testing capacity with the acquisition of three additional Ella™ instruments, which have been installed at its Melbourne facility to support this phase.
Clinical Validation and FDA Submission Timeline
Preparations for the subsequent clinical validation (CV) phase are already underway, including engagement with an external laboratory and finalisation of study protocols. CV will leverage samples collected from the company's pivotal U.S. clinical trial, alongside control and confounding condition samples, to generate the clinical evidence required for FDA submission. Subject to manufacturing timelines, Cleo anticipates completing AV in approximately four months, with FDA 510(k) submission targeted for the first half of calendar year 2027.
Strategic Manufacturing Partnership with Bio-Techne
Cleo’s collaboration with Bio-Techne, which began earlier this year, is central to its manufacturing and validation strategy. Bio-Techne’s expertise and the Ella™ platform underpin the production of the test kits essential for both analytical and clinical validation. This partnership is a key enabler for scaling up production ahead of commercial launch, which is planned following successful FDA clearance.
Implications for Ovarian Cancer Diagnostics
Ovarian cancer remains one of the deadliest cancers affecting women, largely due to late diagnosis and the absence of effective screening tools. Cleo’s test, based on the CXCL10 biomarker, aims to fill this critical gap by enabling earlier and more accurate detection. The company’s staged development strategy targets pre-surgical triage initially, with future expansions into recurrence monitoring and global screening. The successful progression through analytical and clinical validation phases will be pivotal in realising these ambitions.
Bottom Line?
Cleo’s move into analytical validation brings it closer to FDA submission, but manufacturing timelines and validation outcomes will be crucial to watch.
Questions in the middle?
- Will the analytical validation confirm assay reproducibility across batches as planned?
- How might manufacturing timelines from Bio-Techne impact the overall FDA submission schedule?
- What clinical validation results will emerge from the pivotal U.S. trial samples?